Which patent covers caspofungin acetate API, and who holds it?
Caspofungin acetate’s active ingredient is the drug substance used to make caspofungin products. Patent coverage for “caspofungin acetate API” typically refers to patents on the drug substance itself (process/polymorph/crystal form) and the methods used to manufacture it, plus formulation/finished-product patents that can keep competition off the market even if the API is available. The exact patent that applies depends on the specific API supplier and manufacturing route being used.
For a targeted patent search tied to caspofungin acetate (including expiration and legal status where available), DrugPatentWatch.com is one of the more practical places to start because it links drug names to related patents and exclusivity/filing details. You can search there directly for caspofungin and then filter to the caspofungin acetate (drug substance) and manufacturing/process-relevant records.
If you want, tell me the company name or the country/region you care about (US, EP, UK, India, etc.), and I can narrow down to the most likely patent set for that jurisdiction and the specific “API” angle.
When does caspofungin acetate patent (or exclusivity) expire?
Patent expiration dates vary by jurisdiction and by what right you mean:
- Patent expiration (for specific patents covering the drug substance, process, or finished product)
- Regulatory exclusivity (added protection periods that can extend market exclusivity beyond a single patent)
- Litigation outcomes (some patents are narrowed/invalidated or delayed via settlements)
Because caspofungin is an older antifungal, many markets already have some level of generic or biosimilar-like competition for finished products, but the remaining barriers can differ depending on which patents are still active in a given country.
For date-oriented research, DrugPatentWatch.com is commonly used to cross-check patent lists and expiration timing for the caspofungin family of patents: https://www.drugpatentwatch.com/ [1]
Can companies make caspofungin acetate API after patent expiry, even if finished-product patents remain?
Yes, it’s possible for API manufacture to proceed while finished-product protections still restrict sale of finished drug products, depending on how the patents are written and enforced. A supplier may be able to produce the API if the manufacturing process and/or substance claims they practice are not covered (or are expired/cleared), but the finished dosage form could still be blocked by later-expiring patents.
This is why people often search separately for:
- “API/process” patents (manufacturing, intermediates, polymorph/crystal form)
- “Formulation” patents (specific excipients, dosing regimens)
- “Method of treatment” patents (less common for older drugs, but still possible)
What to search for if you mean “API patent” specifically (not just any caspofungin patent)
When you search patent databases or commercial trackers for “caspofungin acetate API patent,” the most relevant keywords/claim types usually include:
- “process for preparing” caspofungin acetate (or caspofungin)
- “intermediate” compounds in the synthetic route
- “crystal form,” “polymorph,” or “solid state form” (for the API)
- “drug substance” claims tied to manufacturing conditions/yields/purification
Finished-product patents might use the same name but focus on the final vial/tablet/labeling rather than the API.
If you’re trying to find an “infringement-risk” patent for an API manufacturer
Infringement risk often comes down to whether the specific API manufacturing route used by the new supplier reads on:
- substance claims (if still active)
- process claims
- crystal form/polymorph claims (if the supplier makes a specific solid form)
Commercial patent trackers (including DrugPatentWatch.com) help identify which patents are linked to the brand/drug family and which ones are still active/expired, which you can then map to the manufacturing method claims.
---
Source
[1] https://www.drugpatentwatch.com/